Leigh syndrome and hypertrophic cardiomyopathy in an infant with a mitochondrial DNA point mutation (T8993G)

1994 ◽  
Vol 50 (3) ◽  
pp. 265-271 ◽  
Author(s):  
Gregory M. Pastores ◽  
Filippo M. Santorelli ◽  
Sara Shanske ◽  
Bruce D. Gelb ◽  
Billie Fyfe ◽  
...  
2000 ◽  
Vol 15 (12) ◽  
pp. 830-833 ◽  
Author(s):  
Callum J. Wilson ◽  
Nicholas W. Wood ◽  
James V. Leonard ◽  
Robert Surtees

Neurology ◽  
1997 ◽  
Vol 49 (2) ◽  
pp. 589-592 ◽  
Author(s):  
R. M. Chalmers ◽  
P. J. Lamont ◽  
I. Nelson ◽  
D. W. Ellison ◽  
N. H. Thomas ◽  
...  

2011 ◽  
Vol 15 ◽  
pp. S47-S48
Author(s):  
S. Aguilera-Albesa ◽  
M.E. Yoldi-Petri ◽  
T. Durá-Travé ◽  
J. Rodríguez-Ozcoidi ◽  
A. Pérez-Ocón

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
Y Fujiwara ◽  
K Deguchi ◽  
Y Naka ◽  
M Sasaki ◽  
T Nishimoto ◽  
...  

Abstract Introduction Tissue engineering using human induced pluripotent stem cells-derived cardiomyocytes (hiPSCs-CMs) is one of the potential tools to replicate human heart in vitro. Although there are many publications on 3 dimensional (3D) heart tissues (1), these tissues show fetal like phenotypes. For that reason, several maturation methods such as electrical stimulation and mechanical stress have been investigated (2, 3). However, these methods have been inadequate in differentiating fetal like phenotype tissue from adult tissues. Previously, we identified a novel compound, T112, which induced hiPSCs-CMs maturation from approximately 9,000 compounds using Troponin I1-EmGFP and Troponin I3-mCherry double reporter hiPSCs-CMs. This compound enhanced morphological and metabolic maturation of hiPSCs-CMs via estrogen-rerated receptor gamma activation Purpose We hypothesized that our novel compound, T112, in combination with mechanical stress could result in further maturation of 3D heart tissue. Therefore, our specific aim is to develop a novel maturation method applicable to genetic disease model of HCM using 3D heart tissue combined with T112. Methods We constructed 3D heart tissue mixed with fibroblast and double reporter hiPSCs-CMs by the hydrogel methods using Flex cell system®. We added T112 with or without mechanical stretching to 3D tissue from 7 to 15 days after 3D heart tissue was constructed. Then we measured maturation related phenotype such as sarcomere gene expression, mitochondrial DNA content and cell size. Results Similar to hiPSCs-CM, the addition of T112 to the constructed 3D heart tissue significantly increased TNNI3 mRNA compared to that of DMSO. Furthermore, T112 treated 3D heart tissue showed increased cell size and oblong shape. Next, in order to promote more maturation of 3D heart tissue, we performed mechanical stretching with the addition of T112. The combination of T112 with mechanical stretching showed higher expression of mCherry, a reporter protein for TNNI3 expression, and higher isotropy of sarcomere alignment in 3D heart tissue than that with the static condition. Furthermore, 3D heart tissue in the treatment of T112 with or without mechanical stretching showed higher mitochondrial DNA content compared to the respective DMSO controls. Interestingly, we applied this combination method to hiPSCs carrying MYH7 R719Q mutation which is known to cause hypertrophic cardiomyopathy, and the 3D heart tissue composed of cardiomyocytes derived from mutant iPSCs demonstrated increased sarcomere disarray compared to isogenic wild-type 3D heart tissue. Conclusion These results suggest that the combination of T112 and mechanical stretching promotes metabolic and structural maturation of 3D heart tissue and would be useful for creating a HCM disease model. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): T-CiRA project, Takeda Pharmaceutical Company Limited


2006 ◽  
Vol 51 (4) ◽  
pp. 865-873 ◽  
Author(s):  
Catherine Theves ◽  
Christine Keyser-Tracqui ◽  
Eric Crubezy ◽  
Jean-Pierre Salles ◽  
Bertrand Ludes ◽  
...  

1998 ◽  
Vol 43 ◽  
pp. 127-127
Author(s):  
Sara Shanske ◽  
Denise Kirby ◽  
Claudio Bruno ◽  
Barbara Garavaglia ◽  
Filippo M Santorelli ◽  
...  

2020 ◽  
pp. 325-342
Author(s):  
Perry Elliott ◽  
Pier D. Lambiase ◽  
Dhavendra Kumar

This chapter begins by defining the mitochondrial genome, and the subsequent assessment of suspected mitochondrial DNA (mtDNA) disorders. The incidence and prevalence of cardiac involvement in mitochondrial disorders is covered, including the probably under-reporting of this. Different cardiovascular phenotypes associated with mitochondrial disease (arrhythmias, hypertrophic cardiomyopathy, Barth syndrome etc.) are all described, and then the clinical management of the diseases are explained. As there is no fixed treatment, pharmacological regimens to avoid, and other approaches are also included.


2020 ◽  
Vol 52 (1) ◽  
pp. 15-19
Author(s):  
J. Rose ◽  
T. Kraft ◽  
B. Brenner ◽  
J. Montag

Point mutation R723G in the MYH7 gene causes hypertrophic cardiomyopathy (HCM). Heterozygous patients with this mutation exhibit a comparable allelic imbalance of the MYH7 gene. On average 67% of the total MYH7 mRNA are derived from the MYH7R723G-allele and 33% from the MYH7WT allele. Mechanisms underlying mRNA allelic imbalance are largely unknown. We suggest that a different mRNA lifetime of the alleles may cause the allelic drift in R723G patients. A potent regulator of mRNA lifetime is its secondary structure. To test for alterations in the MYH7R723G mRNA structure we used selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) analysis. We show significantly different SHAPE reactivity of wild-type and MYH7R723G RNA, which is in accordance with bioinformatically predicted structures. Thus, we provide the first experimental evidence for mRNA secondary structure alterations by the HCM point mutation. We assume that this may result in a prolonged lifetime of MYH7R723G mRNA in vivo and subsequently in the determined allelic imbalance.


Sign in / Sign up

Export Citation Format

Share Document